Corbus Pharmaceuticals Holdings, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Corbus Pharmaceuticals Holdings, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.91
2.44
4.82
36.1
3.94
0.88
0
Research and development
15.4
26
48.6
89.6
98.3
36.4
16.1
31.2
32.2
70.1
General and administrative
6.46
8.96
13
23.6
28.5
20.4
18.7
13.9
16.5
15.2
Operating expenses
21.9
35
61.6
113
127
56.9
39.8
45.1
48.7
85.3
Operating income
-20
-32.6
-56.7
-77.1
-123
-56
-39.8
-45.1
-48.7
-85.3
Interest expense
0
0
0
1.13
2.71
3.1
3.86
1.87
0
Interest income
0.98
1.23
Other non-operating income
-0.01
0.14
1.08
5.65
11.5
10.3
-2.51
0.47
8.51
6.77
Income tax
0
0
Net income to minority interests
-40.2
-78.5
Net income
-20
-32.4
-55.7
-71.5
-111
-45.6
-42.3
-44.6
-40.2
-78.5
EBITDA
-19.9
-32.3
-56.3
-76.4
-122
-55
-39.1
-44.4
-48.1
-85.1
EPS, basic
-14.77
-19.59
-29.53
-33.75
-42.79
-11.15
-10.15
-10.31
-3.68
-5.90
EPS, diluted
-14.77
-19.59
-29.53
-33.75
-42.79
-11.15
-10.15
-10.31
-3.68
-5.90
Shares, basic (weighted)
1.37
1.67
1.89
2.12
2.59
4.09
4.17
4.33
10.9
13.3
Shares, diluted (weighted)
1.37
1.67
1.89
2.12
2.59
4.09
4.17
4.33
10.9
13.3
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
15
62.5
41.7
31.7
85.4
25
17
13.7
17.2
28.5
Short-term investments
72.6
42.2
7.18
132
135
Other current assets
0.93
2.81
2.49
3.72
3.71
2.37
0.79
2.45
3.63
3.02
Total current assets
17.4
65.5
44.2
38.2
92.1
100
60.2
23.5
153
167
Property, plant and equipment
0.44
1.43
2.71
5.08
4.07
2.39
1.61
0.97
0.39
0.16
Lease right-of-use assets
5.82
5.25
4.61
3.88
3.06
2.13
1.08
Other non-current assets
0.04
0.04
0.08
0.23
0.05
0.16
0.21
0
Total assets
17.9
67
47
49.1
102
108
66.3
28.3
156
168
Accounts payable
3.42
3.13
6.35
11.1
7.38
1.78
2.17
3.18
4.79
2.22
Accrued liabilities
3.26
4.74
9.85
22.4
22
10.1
6
11
5.43
16.8
Deferred revenue
1.94
1.46
Short-term debt
3.09
2.8
15.9
Total current liabilities
8.9
8.2
18.1
34.9
31.9
17
12.6
31.9
11.8
20.7
Long-term debt
18
15.6
16
0
Lease liabilities
1.38
8.1
7.09
5.96
4.68
3.24
1.63
0
Other non-current liabilities
0
0
0.02
0.02
0.04
0
Total liabilities
8.97
9.19
19.5
43
57
38.6
33.3
35.2
13.5
20.7
Total debt
21.2
21.2
21.6
17.9
Paid-in capital
42.2
123
149
199
349
419
425
430
619
703
Retained earnings
-33.3
-65.7
-121
-193
-304
-350
-392
-437
-477
-555
Other comprehensive income
-0.06
-0.13
-0
0.04
-0.05
Shareholders' equity
8.92
57.8
27.5
6.16
45.3
69.1
33
-6.91
142
148
Total equity
8.92
57.8
27.5
6.16
45.3
69.1
33
-6.91
142
148
Total liabilities and equity
17.9
67
47
49.1
102
108
66.3
28.3
156
168
Shares outstanding
1.48
1.85
1.9
2.15
3.28
4.17
4.17
4.42
12.2
17.6
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-20
-32.4
-55.7
-71.5
-111
-45.6
-42.3
-44.6
-40.2
-78.5
Depreciation and amortization
0.09
0.26
0.49
0.74
1.12
1
0.76
0.64
0.59
0.23
Stock-based compensation
3.16
5.69
7.61
12
12.5
9.48
5.72
3.47
6.15
6.29
Change in receivables
-1
1
12.5
5
Change in payables
1.89
-0.89
3.9
4.37
-3.47
-5.96
-0.26
1.03
1.6
-2.35
Cash from operations
-13.6
-27.8
-30.1
-45.7
-99.7
-48.2
-37.5
-36.1
-41.8
-64.5
Capital expenditures
-0.35
-0.71
-2.3
-2.74
-0.48
-0.05
-0.01
0
0
-0.01
Purchases of investments
-87.3
-86.3
-33.9
-181
-163
Sales and maturities of investments
13.9
116
69.5
59.5
161
Cash from investing
-0.35
-0.71
-2.3
-2.74
-0.48
-73.4
30.1
35.6
-121
-1.64
Debt issued
18.8
1.38
Debt repaid
-1.5
Stock issued
16.7
78.9
12.1
40.7
142
62.6
0.05
182
77.4
Cash from financing
16.7
76
11.4
38.5
155
60.8
-0.53
-2.82
167
77.4
Net change in cash
2.82
47.5
-20.9
-10
54.7
-60.8
-8
-3.28
3.47
11.3
Free cash flow
-13.9
-28.5
-32.4
-48.5
-100
-48.2
-37.6
-36.1
-41.8
-64.5
Interest paid
0.01
0.01
0.01
0.03
0.63
1.74
1.97
2.61
2.82
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $7.14 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-99.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-80.2%
Net income / average total assets.
Return on invested capital (ROIC)
-107.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
3.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
64.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
26.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
7.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
36.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
10.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
22.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
47.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
38.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.71x
Current assets / current liabilities.
Quick ratio
5.49x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.49x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$4.47
Cash from operations / diluted weighted shares.
Book value per share
$5.48
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.35x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.35x
Market cap / tangible book value, when positive.
Earnings yield
-73.8%
Net income / market cap (the inverse of P/E).
Was Corbus Pharmaceuticals Holdings, Inc. profitable in fiscal 2025?
No. It reported a net loss of $78.5M.
How much free cash flow did Corbus Pharmaceuticals Holdings, Inc. generate in fiscal 2025?
Cash from operations of $64.5M minus capital expenditures of $7.0K left free cash flow of -$64.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.